Small Pharma: Top 10 Undervalued Biotechnology Industry Stocks (DMT)
Small Pharma is now ranked among the top 10 undervalued stocks in the Biotechnology industry on the Toronto Stock Exchange or TSX Venture Exchange. A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to determine the intrinsic (true) worth of a company. Valuation methodology provided by Stockcalc (see below).
Biotechnology: Biotech and biopharmaceutical companies engaged in research, discovery, development, and production of innovative drug and drugrelated technologies. Stocks in this category are held primarily for capital appreciation.
|Symbol||Name||Close Price ($)||Valuation ($)||Difference||Average Vol (30D)||Market Cap ($M)||Yield (%)||P/E Ratio|
|TBP-T||Tetra Bio Pharma||0.03||0.06||0.03|
More about Small Pharma
All data provided as-at market close May 11, 2023. The list is sorted by stocks with the greatest percentage difference between valuation and price. Small Pharma Small Pharma Inc is a neuropharmaceutical company. It is committed towards the development of effective therapeutic treatments for mental health disorders. Small Pharma is developing N,N-dimethyltryptamine and a pipeline of novel patent-protected deuterium-enriched tryptamine compounds in combination with psychotherapy as potential rapid onset, sustained treatments for depression and other mental health disorders. Small Pharma is listed under DMT on the TSX Venture Exchange.
StockCalc is a Canadian fintech company specializing in fundamental valuations for North American stocks and ETFs. StockCalc valuations (https://www.stockcalc.com/Resources) can help determine if a stock is undervalued. StockCalc's Weighted Average Valuation (WAV) is based on a proprietary calculation using model and analyst inputs, including: Discounted Cash Flow (DCF), Price & Other Comparables, Multiples, Adjusted Book Value (ABV) and Analyst Consensus
Artificial intelligence at Report on Business
Artificial Intelligence at Report on Business Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.